Skip to main content
SpringerLink
Log in

Raloxifene is an effective option for the prevention of vertebral fractures associated with postmenopausal osteoporosis

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

Notes

  1. 1 The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Wellington K, Plosker GL. Management of postmenopausal osteoporosis: defining the role of raloxifene. Dis Manage Health Outcomes 2003; 11(10): 673–92

    Article  CAS  Google Scholar 

  2. Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999; 10(4): 259–64

    Article  PubMed  CAS  Google Scholar 

  3. North American Menopause Society. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause 2002; 9(2): 84–101

    Google Scholar 

  4. Committee on Gynecologic Practice. Bone density screening for osteoporosis. Int J Gynecol Obstet 2002 Jun; 77(3): 299–301

    Article  Google Scholar 

  5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288(3): 321–33

    Article  PubMed  CAS  Google Scholar 

  6. Eli Lilly and Company. Evista: raloxifene hydrochloride 60 mg tablets [online]. Available from URL: http://pi.lilly.com [Accessed 2004 Aug 19]

  7. Merck & Co. Inc. Fosamax [online]. Available from URL: http://www.fosamax.com [Accessed 2004 Aug 19]

  8. Procter & Gamble Pharmaceuticals. Actonel (risedronate sodium tablets) [online]. Available from http://www.actonel.com [Accessed 2004 Aug 19]

  9. Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003; 10(4): 337–44

    Article  PubMed  Google Scholar 

  10. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637–45

    Article  PubMed  CAS  Google Scholar 

  11. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002 Aug; 87(8): 3609–17

    Article  PubMed  CAS  Google Scholar 

  12. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002 May 27; 162: 1140–3

    Article  PubMed  CAS  Google Scholar 

  13. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001; 65(2): 125–34

    Article  PubMed  CAS  Google Scholar 

  14. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287(7): 847–57

    Article  PubMed  CAS  Google Scholar 

  15. Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 2000 Jan 15; 34: 65–73

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raloxifene is an effective option for the prevention of vertebral fractures associated with postmenopausal osteoporosis. Drugs Ther. Perspect 20, 1–5 (2004). https://doi.org/10.2165/00042310-200420110-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200420110-00001

Keywords

Search

Navigation